A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 7, 1997, Pages 897-902

  Baxter, Andrew D ^a   Bird, John ^a   Bhogal, Ranjev ^a   Massil, Tracy ^a   Minton, Kevin J ^a   Montana, John ^a   Owen, David A ^a  

^a Chiroscience Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ISOENZYME; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; TRIPEPTIDE DERIVATIVE;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

EID: 0030936876     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00125-X     Document Type: Article

References (22)

1. (a) Murphy, G. J. P.; Murphy, G.; Reynolds, J. J. FEBS Lett. 1991, 289, 4-7
2. (b) Woessner, J. F. FASEB J. 1991, 5, 2145-2154
3. (c) Johnson, W. H.; Roberts, N. A.; Borkakoki, N. J. Enzyme Inhib. 1987, 2, 1-22
4. (d) Henderson, B.; Docherty, A. J. P.; Beeley, N. R. A. Drugs Future 1990, 15, 495-508
5. (e) Emonard, H.; Grimaud, H. Cell. Mol. Biol. 1990, 36, 131-153
6. (f) Wahl, R. C.; Dunlap, R. P.; Morgan, B. P. In Annual Reports in Medicinal Chemistry; Academic Press Inc.: New York, 1989; Vol 25.
7. (g) Rich, D. H. In Comprehensive Medicinal Chemistry; Hansch, C., Sammes, P. G., Taylor J. B., Eds.; Pergamon Press: New York, 1990.
8. Cawston, T. E. British Medical Bulletin 1995, 51, 385-401.
9. Nagase, H.; Barrett, A. J.; Woessner, J. F. In Matrix Metalloproteinases and Inhibitors, Matrix Supplement No 1; Birkedal-Hansen, H., Werb, Z., Welgus, H. G., Van Wart, H. E., Eds.; Gustav Fischer Verlag: New York, 1992; pp 421-424.
10. (a) Dean, D. D.; Martel-Pelletier, J.; Pelletier, J.-P.; Howell, D. S.; Woessner, J. F. Clin. Invest. 1989, 84, 678.
11. (b) Hasty, K. A.; Reife, R. A.; Kang, A. H.; Stuart, J. M. Arth. Rheum. 1990, 33, 388.
12. (c) Walakovits, L. A.; Bhardwaj, N.; Gallick, G. S.; Lark, M. W. Arth. Rheum. 1992, 35, 35
13. (d) Liotta, L. A.; Rao, C. N. Lab. Invest. 1983, 49, 636-649
14. (e) Reich, R.; Stratford, B.; Klein, K.; Martin, G. R.; Mueller, R. A.; Fuller, G. C. In Metastasis: Ciba Foundation Symposium; Wiley: Chichester, 1988; pp 193-210.
15. For recent reviews of small-molecule synthetic inhibitors see (a) Schwartz, M. A.; Van Wart, H. E. In Progress in Medicinal Chemistry; Ellis, G. P.; Luscombe, D. K., Eds.; Elsevier Science Publishers B. V.: The Netherlands 1992; Vol 29
16. (b) Beckett, R. P.; Davidson, A. H.; Drummond, A. H.; Huxley, P.; Whittaker, M. Drug Discovery Today 1996, 1, 16-26
17. (c) Porter, J. R.; Millican, T. A.; Morphy, J. R. Exp. Opin. Ther. Patents 1995, 5, 1287-1296.
18. For general reviews of thiol-based ligands, see reference 5, above. Some examples of mercaptoacyl MMP inhibitors similar to 1 are known in the literature. See ref 1(c), above, and Gray, R. D.; Sanelli, H. H.; Spatola, A. F. Biochem. Biophys. Res. Commun., 1981, 101, 1251-1258.
19. 1H NMR and mass spectroscopy.
20. 50 values quoted are geometric means of at least three determinations. They were determined using fluorimetric assays for the MMP enzyme inhibition, based on the procedure described by Knight, G. C.; Willenbrock, F.; Murphy, G. FEBS 1992, 296, 263-266.
21. For MMP-8 structure with bound hydroxamate inhibitor, see: Stams, T.; Spurlino, J.C.; Smith, D.L.; Wahl, R.C.; Ho, T.F.; Qoronfleh, M.W.; Banks, T.M.; Rubin, B. Nature Struct. Biol. 1994, 1, 119-123.
22. For details of the Adjuvant Arthritic Rat model of arthritis, see Newbold, B. B. Brit. J. Pharmacol. 1963, 21, 127.